This tools helps you project your potential return on investments for the given stock, for a specified amount over a per-defined period of time.
If I had made LUMPSUM investment of ₹ 1,00,000
in INDOCO REMEDIES LTD.
My investment would be worth ₹ 1,41,900 with a Gain of 41.90 %
- MRO-TEK REALTY LTD
- GOKALDAS EXPORTS LTD.
- RCC CEMENTS LTD.
- SUTLEJ TEXTILES & INDUSTRIES LIMITED
- OCL INDIA LTD.
- IM+ CAPITALS LIMITED
- ALUFLUORIDE LTD.
- FOUNDRY FUEL PRODUCTS LTD.
- ADVANCE SYNTEX LIMITED
- KIFS FINANCIAL SERVICES LTD.
- MEDICAMEN BIOTECH LTD.
- KALLAM TEXTILES LTD
- GATEWAY DISTRIPARKS LTD.
- PVR LTD.
- NIYOGIN FINTECH LIMITED
- SOUTH INDIA PAPER MILLS LTD.
- ADVANCE LIFESTYLES LTD.
- MAESTROS ELECTRONICS & TELECOMMUNICATIONS SYSTEMS LTD
- HATHWAY BHAWANI CABLETEL & DATACOM LTD.
- BLUE CHIP TEX INDUSTRIES LTD.
Frequently Asked Questions
What is the Share price of INDOCO REMEDIES LTD. (INDOCO)?
Can I buy INDOCO REMEDIES LTD. (INDOCO) shares?
How do I buy INDOCO REMEDIES LTD. (INDOCO) from Angel One?
- Direct investment: You can buy INDOCO REMEDIES LTD. (INDOCO) shares by opening a Demat account with Angel One.
- Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to INDOCO REMEDIES LTD. (INDOCO) shares.
In which sector do INDOCO REMEDIES LTD. (INDOCO) belong?
Today's live share price for INDOCO REMEDIES LTD. is NSE: ₹ 366.90, BSE: ₹ 367.35 with a current market capitalization of .
Indoco Remedies (Indoco) is a Mumbai-based pharmaceutical company that focuses on formulations, with some presence in contract manufacturing and research. It also trades some active pharma ingredients (APIs) manufactured by a group company. Currently, Indoco has a presence in the therapeutic segments including anti-infective, anti-cold preparation, opthalmic, anti-spasmodic, stomatology, anti-inflammatory and anti-fungal. As per AC Nielsen ORG-MARG market survey (August 2004) of doctors, Indoco ranked first in the stomatology, ninth in the opthalmic and twelve in the pediatric segments in terms of prescription generation in the domestic market. In the overall pharma industry, Indoco is ranked 34th as per AC Nielsen ORG-MARG Retail Audit, but ranked 23rd in terms of prescription generation, indicating the strength of its marketing network. Further, the company last year launched a new super specialty division, with focus on diabetic and cardio-vascular segments. Its entry into the lifestyle segment with a strong presence in the prescription segment would augur well for the higher- than-average industry growth. Currently, Indoco has four manufacturing facilities. Two are located in Mumbai and two in Goa, and an R&D centre in Mumbai. The solid dosage facility in Goa has been accredited by UK-Medicines and Healthcare Products Regulatory Agency (MHRA), and the sterile plant of Goa has been designed as per US Food and Drug Administration (FDA) norms. On the selling front, it has a marketing network of 1,248 medical representatives.Read more